Update of Natural Products and Their Derivatives Targeting Epstein–Barr Infection

Rosamaria Pennisi,Paola Trischitta,Marianna Costa,Assunta Venuti,Maria Pia Tamburello,Maria Teresa Sciortino

DOI: https://doi.org/10.3390/v16010124

2024-01-16

Viruses

Abstract:Epstein–Barr (EBV) is a human γ-herpesvirus that undergoes both a productive (lytic) cycle and a non-productive (latent) phase. The virus establishes enduring latent infection in B lymphocytes and productive infection in the oral mucosal epithelium. Like other herpesviruses, EBV expresses its genes in a coordinated pattern during acute infection. Unlike others, it replicates its DNA during latency to maintain the viral genome in an expanding pool of B lymphocytes, which are stimulated to divide upon infection. The reactivation from the latent state is associated with a productive gene expression pattern mediated by virus-encoded transcriptional activators BZLF-1 and BRLF-1. EBV is a highly transforming virus that contributes to the development of human lymphomas. Though viral vectors and mRNA platforms have been used to develop an EBV prophylactic vaccine, currently, there are no vaccines or antiviral drugs for the prophylaxis or treatment of EBV infection and EBV-associated cancers. Natural products and bioactive compounds are widely studied for their antiviral potential and capability to modulate intracellular signaling pathways. This review was intended to collect information on plant-derived products showing their antiviral activity against EBV and evaluate their feasibility as an alternative or adjuvant therapy against EBV infections and correlated oncogenesis in humans.

virology

What problem does this paper attempt to address?

The paper aims to address the following issues:

1. **Overview of the research progress on natural products and their derivatives against Epstein–Barr (EBV) infection**: The paper reviews the antiviral activity of plant-derived natural products against EBV infection and evaluates their feasibility as alternative or adjunct therapies.

2. **Exploration of the relationship between EBV infection and related cancers**: EBV is a γ-herpesvirus that can establish persistent latent infection in B lymphocytes and actively replicate in the epithelial cells of the oral mucosa. The paper details the infection mechanisms of EBV in different cell types and its association with various cancers (such as Burkitt's lymphoma, nasopharyngeal carcinoma, and gastric cancer).

3. **Investigation of the potential of natural compounds to combat EBV infection**: Although there are currently no specific FDA or EMA-approved anti-EBV drugs, many natural compounds have been extensively studied due to their low toxicity and broad biological activity. The paper explores how these natural compounds exert antiviral effects by inhibiting different replication steps of EBV and evaluates their effectiveness as potential therapeutic agents.

In summary, the focus of this paper is to collect and summarize information on plant-derived products with anti-EBV activity and to assess their potential as alternative or adjunct therapies for the prevention or treatment of EBV infection and related tumors.